Glaucoma Treatment Market Size was valued at USD 5.9 Billion in 2022. The glaucoma treatment market industry is projected to grow from USD 6.1 Billion in 2023 to USD 8.0 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.50% during the forecast period (2024 - 2032). Rising awareness about the condition to offer growth prospects and intense focus on advanced technology for product development are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The glaucoma treatment market is characterized by significant advancements in technology. Innovations such as minimally invasive surgical techniques, sustained-release drug delivery systems, and the integration of artificial intelligence in diagnostics are reshaping the landscape. These technological breakthroughs not only improve the precision and efficacy of glaucoma treatments but also offer patients less invasive options, quicker recovery times, and enhanced long-term management strategies. This factor drives the market CAGR.
Additionally, early detection and diagnosis of glaucoma are becoming focal points in the market trends. There is a growing emphasis on developing and adopting diagnostic tools that enable early identification of glaucoma risk factors. Advances in imaging technologies, such as optical coherence tomography (OCT) and visual field testing, are enabling healthcare professionals to detect glaucoma at earlier stages. Early intervention allows for more effective management, preventing or minimizing vision loss. The market is witnessing a shift towards proactive screening programs and the integration of these advanced diagnostic tools into routine eye care practices.
Another notable trend is the exploration of combination therapies for glaucoma treatment. Researchers and pharmaceutical companies are focusing on developing medications that combine different classes of drugs or therapeutic approaches to address multiple factors contributing to intraocular pressure and optic nerve damage. Combination therapies aim to provide enhanced efficacy, improve patient adherence, and potentially reduce the need for multiple medications. This trend reflects the industry's pursuit of comprehensive solutions that can better control glaucoma progression and improve overall patient outcomes. For instance, Teva Pharmaceuticals announced the first generic version of AZOPT (brinzolamide ophthalmic suspension) 1 percent in March 2021 in the United States to treat open-angle glaucoma and ocular hypertension. The company's product portfolio has been strengthened as a result of this. Thus, driving the glaucoma treatment market revenue.
The glaucoma treatment market segmentation, based on Disease Type includes Open angle glaucoma, Angle closure glaucoma, Others. Open-angle glaucoma is the most common form of glaucoma, characterized by a gradual increase in intraocular pressure, leading to optic nerve damage and vision loss. This dominance is attributed to the higher prevalence of open-angle glaucoma globally, making it a primary focus for treatment and management strategies. Simultaneously, the fastest-growing category is angle-closure glaucoma. This form of glaucoma is characterized by a sudden and severe increase in intraocular pressure, often requiring immediate medical attention. The growing awareness of angle-closure glaucoma and advancements in diagnostic technologies contribute to the increasing identification of cases.
The glaucoma treatment market segmentation, based on Drug Class, includes Prostaglandin analogs, Beta blockers, Adrenergic agonists, Carbonic anhydrase inhibitors, others. Prostaglandin analogs emerge as the dominating drug class. Prostaglandin analogs are widely prescribed due to their effectiveness in lowering intraocular pressure, a key factor in managing glaucoma. The convenience of once-daily dosing and minimal side effects contribute to their popularity among healthcare practitioners and patients alike. Simultaneously, beta blockers represent the fastest-growing category in the glaucoma treatment market. The growth of beta blockers is propelled by their ability to reduce intraocular pressure by decreasing the production of aqueous humor. Ongoing research and development initiatives, coupled with advancements in beta blocker formulations, contribute to the expanding adoption of this drug class.
The glaucoma treatment market segmentation, based on distribution channel, includes Hospital Pharmacy, Retail Pharmacy, Online Pharmacy. Hospital pharmacies take the lead as the dominating distribution channel. Hospital pharmacies play a crucial role in providing immediate and comprehensive healthcare solutions. With their extensive range of pharmaceuticals, including specialized glaucoma medications, hospital pharmacies become the primary choice for patients seeking timely and expert guidance. Concurrently, the online pharmacy segment emerges as the fastest-growing category in the glaucoma treatment market. The rapid expansion of e-commerce and digital platforms has revolutionized the accessibility of pharmaceuticals.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American glaucoma treatment market area will dominate this market, owing to advanced healthcare infrastructure, a high incidence of glaucoma; rigorous regulatory standards will boost market growth in this region.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe glaucoma treatment market accounts for the second-largest market share due to the accessible healthcare services, technological advancements, a focus on research and development. Further, the German glaucoma treatment market held the largest market share, and the UK glaucoma treatment market was the fastest growing market in the European region
The Asia-Pacific Glaucoma treatment Market is expected to grow at the fastest CAGR from 2024 to 2032. This is due to increasing elderly population, high incidence of glaucoma. Moreover, China’s glaucoma treatment market held the largest market share, and the Indian glaucoma treatment market was the fastest growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the glaucoma treatment market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, glaucoma treatment industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the glaucoma treatment industry to benefit clients and increase the market sector. In recent years, the glaucoma treatment industry has offered some of the most significant advantages to medicine. Major players in the glaucoma treatment market, including AERIE Pharmaceuticals, Inc., Cipla Inc., Akorn Operating Company LLC, AbbVie, Bausch & Lomb Incorporated, Inoteck Pharmaceuticals, Merck & Co., Inc., Novartis AG., and others, are attempting to increase market demand by investing in research and development operations.
Aerie Pharmaceuticals is a pharmaceutical company focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases, and other diseases of the eye. Please note that the information might have changed since then, and I recommend checking the latest sources or the company's official website for the most up-to-date details on Aerie Pharmaceuticals, including their products, pipeline, and any recent developments. Aerie Pharmaceuticals and Santen Pharmaceuticals entered into a partnership agreement in December 2021. This partnership will lead to development and marketing of product for glaucoma therapy which included Rhopressa/Rhokiinsa and Rocklatan/Roclanda.
Nicox SA is a French international ophthalmic company specializing in the development of innovative solutions for eye care. The company is involved in the research, development, and commercialization of ophthalmic products. It has a focus on developing therapies for eye diseases, including glaucoma and other ophthalmic conditions. Nicox SA declared in October 2022 that NCX 470 0.1%, the company's medication, successfully treated intraocular pressure (IOP) in Phase 3 clinical studies.
October 2019: by the European Journal Of Ophthalmology, patients with open-angle glaucoma or ocular hypertension were given the twice-daily 1% of brinzolamide /0.2% of brimonidine (twice daily) with the fixed-dose combination (BBFC) as an addition to a prostaglandin analog to assess the additive intraocular pressure-lowering impact.
June 2022: The United States Food and Drug Administration announced the approval of OMLONTI eye drops developed by Santen Pharmaceutical Co., Ltd., and UBE Corporation. OMLONTI reduces high Intraocular Pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
| Report Attribute/Metric | Details |
| Market Size2022 | USD 5.9 Billion |
| Market Size 2023 | USD 6.10 Billion |
| Market Size2032 | USD 8.04 Billion |
| Compound Annual Growth Rate (CAGR) | 3.50% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Disease Type, Drug Class, Distribution Channel and Region |
| Geographies Covered | North America, Europe, AsiaPacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | AERIE Pharmaceuticals, Inc., Cipla Inc., Akorn Operating Company LLC, AbbVie, Bausch & Lomb Incorporated, Inoteck Pharmaceuticals, Merck & Co., Inc., Novartis AG |
| Key Market Opportunities | · Rising awareness about the condition to offer growth prospects |
| Key Market Dynamics | · Intense focus on advanced technology for product development |
Frequently Asked Questions (FAQ) :
The glaucoma treatment market size was valued at USD 5.9 Billion in 2022.
The global market is projected to grow at a CAGR of 3.50% during the forecast period, 2024-2032.
North America had the largest share in the global market
The key players in the market are AERIE Pharmaceuticals, Inc., Cipla Inc., Akorn Operating Company LLC, AbbVie, Bausch & Lomb Incorporated, Inoteck Pharmaceuticals, Merck & Co., Inc., and Novartis AG.
The open angle glaucoma category dominated the market in 2022.
The Prostaglandin analogs category had the largest share in the global market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
